successful brand building for biotech and pharma products

34
Successful brand building for biotech and pharma products Sahlgrenska Science Park, frukostworkshop Bergenstråhle & Partners 8 April 2016

Upload: johan-oerneblad

Post on 18-Jan-2017

180 views

Category:

Business


0 download

TRANSCRIPT

Page 1: Successful brand building for biotech and pharma products

Successful brand building for biotech and

pharma products

Sahlgrenska Science Park, frukostworkshop

Bergenstråhle & Partners

8 April 2016

Page 2: Successful brand building for biotech and pharma products

20 November 2008:

“GlaxoSmithKline

acquire Alvedon and

Nezeril from

AstraZeneca for

1 770 million SEK”

Page 3: Successful brand building for biotech and pharma products

Agenda

Introduction

Johan and Andreas

Bergenstråhle & Partners

Intellectual asset management

Brands, trademarks and strategy

Patents and trademarks

Page 4: Successful brand building for biotech and pharma products

Bergenstråhle & Partners

Technology

and patentsIP law

Design and

trademarks

Strategy

consulting

=

Page 5: Successful brand building for biotech and pharma products

Intellectual Asset Management

Page 6: Successful brand building for biotech and pharma products

20 November 2008:

“GlaxoSmithKline

acquires Alvedon and

Nezeril from

AstraZeneca for

1 770 million SEK”

Page 7: Successful brand building for biotech and pharma products

Patent supports brand building

• Patents protect inventions

– Protection lasts for 20 years from filing

Product life: indefinite

Patent protection: 20 yrs

Brand protection: indefinite while in use

Page 8: Successful brand building for biotech and pharma products

BRANDS – IN PRACTICE

Page 9: Successful brand building for biotech and pharma products

Brands

• A brand is not a trademark

• A brand is not a logo

• A brand is not a product

• A brand is not a design

• A brand is not a person

• A brand is not an identity

Page 10: Successful brand building for biotech and pharma products

Brands

What is a brand?

• A brand is a persons gut feeling about a product,

service or organization.

• Because brands are defined by individuals, not

by companies, markets or publics.

• It is a gut feeling since individuals are emotional

intuitive beings.

Page 11: Successful brand building for biotech and pharma products

Brands

• A brand is not what YOU say it is…

• It is what THEY say it is!

Page 12: Successful brand building for biotech and pharma products

Brand examples

Page 13: Successful brand building for biotech and pharma products

Brand example

Page 14: Successful brand building for biotech and pharma products

Brand building

• Start by defining your brand

– Who are you?______________

– What do you do? ______________

– Why does it matter? ______________

Page 15: Successful brand building for biotech and pharma products

Consistency is key

Page 16: Successful brand building for biotech and pharma products

Brand structure

Page 17: Successful brand building for biotech and pharma products

GlaxoSmithKline

Page 18: Successful brand building for biotech and pharma products

GlaxoSmithKlein

Page 19: Successful brand building for biotech and pharma products

Patents have long expired – so what

did they acquire?

20 November 2008:

“GlaxoSmithKline

acquires Alvedon and

Nezeril from

AstraZeneca for

1 770 million SEK”

Page 20: Successful brand building for biotech and pharma products

GlaxoSmithKline

• Nezeril protected as a

trademark since 1967

• Alvedon protected as a

trademark since 1948

Page 21: Successful brand building for biotech and pharma products

GlaxoSmithKline

Alvedon:

500mg

20 pills

33 SEK

1,65 SEK/pill

Paracetamol

Orifarm:

500mg

20 pills

12 SEK

0,60 SEK/pill

275%

Page 22: Successful brand building for biotech and pharma products

Choosing a name

• Distinctiveness

• Brevity

• Appropriateness

• Easy spelling and pronunciation

• Likeability

• Extendibility

• Protectability

Page 23: Successful brand building for biotech and pharma products

Define the generic term to avoid

degeneration of the mark

• If the product introduces a new category on the market,

there is a big risk of that the mark becomes the common

name for the product type.

– Jeep, elevator, tomtom, rollerblades, thermos

• To preempt this you should consider to create a generic

descriptor to describe the product type.

– All terrain vehicle, lift, personal navigation device, inline skates,

vacuum flask

• You should also monitor the general use of the mark,

internally and externally

Page 24: Successful brand building for biotech and pharma products

Reasons why companies

register trademarks?

• Clearance – making sure you can

use/register the mark

• Preventing others from use

• Franchising (Licensing)

• Marketing benefits

Page 25: Successful brand building for biotech and pharma products

Trademark - example

Word mark: COCA-COLA, H&M, SPOTIFY, Kinnarps

Figurative/logotype:

3D-trademark:

Page 26: Successful brand building for biotech and pharma products

Control

• Protecting a brand by registration

– What can/should you register?

– TO DO before registering a trademark

• Managing your trademark portfolio

– Oppositions

– Infringements

• Managing your trademark usage (and how

others use your trademarks!)

Page 27: Successful brand building for biotech and pharma products

Trademark clearance

Multicorp.

• Since trademarks is a national right you have to have a

registered trademark in every country where you want to use

your trademark or prevent someone else from using you

trademark.

• Trademark clearance is therefore a relatively complicated and

complex process but is very critical to do BEFORE you launch

your product.

Page 28: Successful brand building for biotech and pharma products

Registering the trademark

• Classification

– 45 different classes (goods and services)

– Costs

• Where to register?

– Sweden – (PRV)

– EU – (EUIPO – former OHIM)

– Elsewhere (madrid protocoll via WIPO or

national filings)

Page 29: Successful brand building for biotech and pharma products

Trademark watches and

oppositions

• Important to monitor other trademark filings

– When you have a registered trademark it is common

to monitor other similar trademarks. This is because

the trademark authorities does not always object to

registration of “similar marks”

• Filing oppositions against other trademarks

– Argue for a likelihood of confusion

• Similarity of the signs

• Similarity of goods and services

• Use requirements (argument or risk)

Page 30: Successful brand building for biotech and pharma products

European Medicines Agency• Läkemedelslagen (2015:315)

• Läkemedelsförordningen

• Läkemedelsverkets föreskrifter om marknadsföring av humanläkemedel (LVFS

2009:6)

• Not allowed to market:– Unauthorized drugs

– Towards children

– Prescription drugs

• §6 All advertising of medicinal products to the public should include at least the

following information: – the name and the current (ie generic) name if the product contains only one active ingredient.

– The information needed for the drug to be used on properly.

– An express, legible invitation to read carefully the instructions on the package leaflet or, if applicable, the

outer package.

Page 31: Successful brand building for biotech and pharma products

Key takeaways

• Manage your intellectual assets AS assets

• Decide your brand

• Trademark clearance

– Right to use: Competitors & marketing law

– Right to register: Absolute/relative hinders

• Manage your rights

• Consistent communication

Page 32: Successful brand building for biotech and pharma products

Brand strategy assessment

• Exclusive to the participants of this seminar and

members at Sahlgrenska Science Park we offer a

Brand Strategy Assessment

• Meeting to review and assess current brand(s) and

strategy

• Specific recommendations to strengthen control and

consistency in use

• Get in touch via [email protected]

Prices excluding VAT and subject to our General terms

Page 33: Successful brand building for biotech and pharma products

Thank you!

20 November 2030:

“GlaxoSmithKline acquires

[INSERT YOUR NAME]

for

1 770 million SEK”

Page 34: Successful brand building for biotech and pharma products

Andreas [email protected]

Johan Ö[email protected]